Cancer drug ixazomib tested as potential MS treatment

NCT ID NCT03783416

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This phase 1b trial is testing whether ixazomib, a drug already used for multiple myeloma, is safe for people with multiple sclerosis. The study will enroll 72 adults with relapsing-remitting or progressive MS. Participants will receive either ixazomib or a placebo for up to 24 months, and researchers will monitor side effects and look for changes in immune markers in the spinal fluid.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ixazomib (NINLARO)
What this could lead to
If it works, this could point toward a new way to control multiple sclerosis by targeting the immune cells that drive the disease.
What could go wrong
This is a very early phase 1b trial with only 72 people, so it is primarily checking safety. It may not show clear benefit, and ixazomib has known side effects from its use in cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Royal London Hospital, Barts Health NHS Foundation Trust

    RECRUITING

    London, Greater London, E1 1BB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.